Visit RezdiraHCP.com to learn more and get patients started.
IMPROVING FIBROSIS & MASH is no longer wishful thinking Rezdira is the first and only treatment for MASH with moderate to advanced fibrosis that activates THR-β directly in the liver 1 For adults with noncirrhotic MASH with moderate to advanced fibrosis, in conjunction with diet and exercise. This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Limitation of Use: Avoid use in patients with decompensated cirrhosis.
Oral, Once- Daily Dosing 1
Dual E icacy 1
Demonstrated Safety 1
Liver- Directed 1
At Week 52, Rezdira delivers statistically significant fibrosis improvement* with no worsening of steatohepatitis and steatohepatitis resolution † with no worsening of fibrosis. 1
MASH=metabolic dysfunction-associated steatohepatitis.
IMPORTANT SAFETY INFORMATION cont.
Renal Impairment The recommended dosage of Rezdira in patients with mild, moderate, or severe renal impairment is the same as in patients with normal kidney function. Hepatic Impairment Avoid use in patients with decompensated cirrhosis (consistent with moderate to severe hepatic impairment). Moderate or severe hepatic impairment (Child-Pugh Class B or C) may increase the risk of adverse reactions. The safety and eectiveness of Rezdira have not been established in patients with cirrhosis. Trial design: MAESTRO-NASH is an ongoing pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled trial in 888 patients with biopsy- confirmed MASH with liver fibrosis (F2 or F3). Patients were randomized 1:1:1 to Rezdira (80 mg or 100 mg) or placebo to evaluate the eicacy and safety at 52 weeks. 1,2 *Fibrosis improvement: ≥1-stage improvement in fibrosis with no worsening of steatohepatitis (defined as no increase in score for ballooning, inflammation, or steatosis). 1 † Steatohepatitis resolution: Resolution of steatohepatitis (score of 0-1 for inflammation, 0 for ballooning, and any value for steatosis) with no worsening of fibrosis. 1
Clinically Significant Interactions Aecting Other Drugs • Statins: Limit daily rosuvastatin and simvastatin dosage to 20 mg. Limit pravastatin and atorvastatin dosage to 40 mg. • CYP2C8 Substrates: Monitor patients more frequently for substrate-related adverse reactions if Rezdira is co-administered with CYP2C8 substrates where minimal concentration changes may lead to serious adverse reactions. USE IN SPECIFIC POPULATIONS Pregnancy There are no available data on Rezdira use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Report pregnancies to Madrigal Pharmaceuticals, Inc. Adverse Event Reporting line at 1-800-905-0324 and visit https://pregnancyregistry.madrigalpharma.com for information about a pregnancy safety study. Lactation There is no information regarding the presence of Rezdira in human or animal milk, the eects on the breast-fed infant, or the eects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Rezdira and any potential adverse eects on the breastfed infant from Rezdira or from the underlying maternal condition. Geriatric Use Numerically higher incidence of adverse reactions have been observed in patients ≥65 years of age compared to younger adult patients.
THR- β =thyroid hormone receptor beta. References: 1. Rezdira. Prescribing Information. Madrigal Pharmaceuticals, Inc. 2. Harrison SA et al. N Engl J Med. 2024;390(6):497-509.
© 2026 Madrigal Pharmaceuticals, Inc. All rights reserved. Rezdira® and its related logo are registered trademarks of Madrigal Pharmaceuticals, Inc.
US-PP-RES-00716-v3 02/26
2/24/26 3:09 PM
Made with FlippingBook flipbook maker